Skip to main content
. 2021 Mar 17;23(7):1033–1041. doi: 10.1093/europace/euab029

Table 1.

Baseline subject characteristics

Cryoballoon CA (n = 107) AAD (n = 111)
Demographics and echocardiographic characteristics
 Age (years) 50.5 (13.1) 54.1 (13.4)
 Sex, male 76 (71.0%) 72 (64.9%)
 Time from first ECG-documented AF to enrolment (years) 0.7 (1.5) 0.8 (2.1)
 Left atrial diameter (short axis) (mm) 37.0 (5.9) 38.0 (4.9)
 Left atrial diameter (long axis) (mm) 46.8 (8.2) 47.7 (6.3)
 Left ventricular ejection fraction (%) 62.8 (5.4) 63.7 (5.4)
EHRA class
 Class I 0 (0.0%) 0 (0.0%)
 Class II 75 (70.1%) 83 (74.8%)
 Class III 30 (28.0%) 25 (22.5%)
 Class IV 2 (1.9%) 1 (0.9%)
Medical history
 Hypertension 33 (30.8%) 40 (36.0%)
 Diabetes 1 (0.9%) 4 (3.6%)
 Hyperlipidaemia 23 (21.5%) 25 (22.5%)
 Myocardial infarction 2 (1.9%) 0 (0.0%)
 Coronary artery disease 2 (1.9%) 1 (0.9%)
 Congestive heart failure 0 (0.0%) 0 (0.0%)
 Stroke 0 (0.0%) 0 (0.0%)
 Transient ischaemic attack 0 (0.0%) 1 (0.9%)
 Valve dysfunction 3 (2.8%) 2 (1.8%)
CHA2DS2-VASc score
 0 49 (45.8%) 38 (34.2%)
 1 33 (30.8%) 40 (36.1%)
 2 13 (12.2%) 15 (13.5%)
 3 4 (3.7%) 10 (9.0%)
 4 3 (2.8%) 2 (1.8%)
Baseline medications
 Anticoagulant 38 (35.5%) 49 (44.1%)
 Acetylsalicylic acid 5 (4.7%) 7 (6.3%)
 β-Blocker 54 (50.5%) 56 (50.5%)
 Calcium channel blocker 9 (8.4%) 15 (13.5%)

Values are n (%) or mean (standard deviation).

AAD, antiarrhythmic drug; AF, atrial fibrillation; CA, catheter ablation; EHRA, European Heart Rhythm Association score.